Neutrophils in pleural infection: untapped potential for targeted therapeutics
- PMID: 40659465
- DOI: 10.1183/13993003.00861-2025
Neutrophils in pleural infection: untapped potential for targeted therapeutics
Conflict of interest statement
Conflict of interest: A. Gilmour reports no potential conflicts of interest. J.D. Chalmers is the chief editor of the European Respiratory Journal and reports grants or contracts from AstraZeneca, Boehringer Ingelheim, Chiesi, Genentech, GlaxoSmithKline, Grifols, Insmed, Pfizer, Sanofi and Zambon.
Comment on
-
Pleural fluid proteomics from patients with pleural infection shows signatures of diverse neutrophilic responses: The Oxford Pleural Infection Endotyping Study (TORPIDS-2).Eur Respir J. 2025 Jul 14;66(1):2500010. doi: 10.1183/13993003.00010-2025. Print 2025 Jul. Eur Respir J. 2025. PMID: 40246538 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources